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Abstract: 
Introduction: Spinal cord injury (SCI) poses a serious threat to human health and typically results in incomplete or 
complete loss of motor and sensory function. The prevalence of SCI is relatively high.  
Aims and objectives: The main objective of the study is to analyze the effects of methotrexate and methylprednisolone 
in spinal cord injury.  
Material and methods: This cross sectional study was conducted in Akhtar Saeed teaching trust hospital, Lahore 
during March 2018 to July 2018.  Data was collected from 50 patients who were suffering from spinal injury. The 
study was divided into two groups, one was control group and one who was treated with MTX.  
Results: The data was collected from 50 patients of SCI. There were significant difference between control groups 
and treated groups. The data shows that the group of patients which was treated with MTX shows more close values 
to the control. But the separate effect shows somehow different values as compared to control.  
Conclusion: It is concluded that MTX therapy could improve the deficiency of MP treatment alone, enhance the neuro 
protective effect, inhibit the activities of inflammatory cytokines, strengthen the anti-oxidative and anti-apoptotic 
effects and increase the clinical therapeutic effect, which could provide new strategies for the control of SCI. 
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INTRODUCTION: 
Spinal cord injury (SCI) poses a serious threat to 
human health and typically results in incomplete or 
complete loss of motor and sensory function. The 
prevalence of SCI is relatively high. Notably, the 
prevalence among the elderly (aged >60 years old) and 
the younger (aged 16–45 years old) have been 
estimated to be ~24 and 49%, respectively, which are 
primarily due to traffic collisions. Although various 
methods of treating SCI are currently used, these 
treatments are not effective since SCIs still result in 
substantial permanent morbidity and mortality. 
Therefore, it is important to develop a novel effective 
method of treating patients with SCI [1]. Primary 
injury often occurs in the spine, leading to SCI. The 
secondary damage includes inflammation, oxidative 
stress, neuronal apoptosis, intracellular and 
extracellular ion imbalance and a series of 
pathological reaction. Therefore, to avoid second 
injury and to promote the survival of axons and 
neurons, therapies aim to reduce or eliminate the 
destructive pathological response and to promote the 
regeneration, repair and functional reconstruction of 
nerve tissue in the chronic phase [2]. 
Now a days low dose methotrexate (MTX) and 
methylprednisolone (MP) has been used for the 
treatment of some inflammatory diseases such as 
secondary spinal cord damage [3]. Low dose MTX 
inhibits the proliferation of lymphocytes in any 
inflammatory response and also decreases the ability 
of leukocytes. Exact mechanism of this drug is still 
unknown but according to some studies it increases the 
adenosine accumulation at the inflammatory sites. 
Adenosine interacts with the receptors and decreases 
the inflammatory cells [4]. 
Aims and objectives: 
The main objective of the study is to analyze the 
effects of methotrexate and methylprednisolone in 
spinal cord injury. 
 
MATERIAL AND METHODS: 
This cross sectional study was conducted in Akhtar 
Saeed teaching trust hospital, Lahore during March 
2018 to July 2018.  Data was collected from 50 
patients who were suffering from spinal injury. The 
study was divided into two groups, one was control 
group and one who was treated with MTX. 
 
Biochemical analysis: 
For biochemical analysis 5cc blood sample was taken 
from vein and sample were processed with phosphate 
buffer saline using homogenizer. Blood was 
centrifuged at 3000rpm for 10 minutes and after that 
pallet was resuspended. Remove the pallet and again 
centrifuge at 3000rpm for 5 minutes. The resultant 
supernatant was separated and used for the 
measurement of MTX activity.  
Statistical analysis: 
The data was collected and analyzed by using the 
SPSS software program (21.0). All results were 
expressed as the mean ± standard deviation (SD).  
 
RESULTS: 
The data was collected from 50 patients of SCI. There 
were significant difference between control groups 
and treated groups. The data shows that the group of 
patients which was treated with MTX shows more 
close values to the control. But the separate effect 
shows somehow different values as compared to 
control.  
Table 1: Values of mean MPO and LPO in all groups 
Groups Variabl
es 
Maximum Minimum Mean±SD 
Control LPO 35.33 30.35 30.00±7.32 
MPO 0.01 0.00 0.00±1.57 
MTX LPO 58.63 54.30 54.30±7.46 
MPO 14.53 11.36 12.50±0.84 
MTX (High dose) LPO 35.00 33.00 32.25±11.68 
MPO 64.14 60.14 62.14±6.14 
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Table 2: Post-Hoc test values for all groups 
No. Of observations Study groups Df P-value 
1 Control 3 0.018* 
2 MTX  
 
1 0.019* 
3 MTX (High dose) 2 0.500 
 
DISCUSSION: 
The present study showed that the MTX significantly 
improved damaged motor function caused by SCI. 
Both compounds and MP combined with other drugs 
have been widely studied; however, to our knowledge, 
this is the first study to show motor function recovery 
in rats after traumatic SCI by a combination of MP and 
MTX at the level of the transcriptome [5]. Our study 
illustrates that the restorative effects of this 
combination therapy may be through the anti-
inflammatory reaction, inhibition of oxidative stress 
and apoptosis and other common gene regulation 
pathways [6]. 
There are many pharmacological agents which 
described or considered as a potentially strong 
therapeutic effects for SCI. Steroids are also accepted 
as a best possible option for the treatment of SCI. They 
have antioxidant and anti-inflammatory and may be 
favorable in a time- and dose-dependent manner [7]. 
They have also anti-edema activities. 
Methylprednisolone (MP) acts through a variety of 
mechanisms to prevent the occurrence of secondary 
SCI and is currently the only food and drug 
administration-approved drug for the treatment of 
acute SCI [8].  
Methotrexate (MTX) is a common anti-rheumatic 
drug that can improve the disease state and has anti-
inflammatory and immunosuppressive effects. MTX 
is generally used to compensate for the poor efficacy 
of glucocorticoid or other anti-rheumatic drugs. MTX 
can also be combined with hormones in early 
rheumatoid arthritis, so as to reduce hormone doses, 
thereby alleviating hormone side effects [9]. MTX can 
be taken long-term because of low cost, various routes 
of administration, steady long-term efficacy and high 
safety; namely, it can be taken as an anchor drug [10]. 
CONCLUSION: 
It is concluded that MTX therapy could improve the 
deficiency of MP treatment alone, enhance the 
neuroprotective effect, inhibit the activities of 
inflammatory cytokines, strengthen the anti-oxidative 
and anti-apoptotic effects and increase the clinical 
therapeutic effect, which could provide new strategies 
for the control of SCI. However, in-depth research into 
the mechanism of these therapeutic effects is required 
owing to the complexity and variety of the 
differentially expressed genes. 
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